How Filler Gel Properties Affect Safety: Lab Research Explained

A 2024 laboratory study injected four hyaluronic acid fillers into a plastic model of a branching facial artery to see what happens to the gel if it enters a vessel. Every product broke into many small fragments, and the pattern depended on the gel's physical properties. For patients, it helps explain why filler complications can affect a wide area of skin, and why clinicians think carefully about which product suits which area.

Why this was studied

Blocked blood flow is a rare but serious complication of filler. One long-standing question is how the damage happens. Does a blob of gel plug one artery, or does it break apart and travel into many smaller vessels downstream? The answer affects how complications are understood and treated, and it is very hard to study directly in people.

Fillers differ in their physical behaviour. Some are firmer and springier; others are softer and more fluid. Researchers describe these properties with laboratory measures, including how elastic the gel is versus how much it flows. The authors wanted to know whether those properties change what happens inside a vessel.

What the researchers did

This was a benchtop experiment with no people or animals involved. The team built a pump-driven model of a branching artery, shaped to resemble the facial artery near the jawline, with tubes narrowing from 8 mm to 1 mm. A clear fluid, not blood, was pumped through at three different flow speeds.

They injected a small, fixed amount (0.2 mL) of each of four hyaluronic acid fillers, chosen because they span a wide range of firmness and flow behaviour. They filmed what happened and measured the size and shape of the fragments.

What they found

All four fillers broke into many fragments at every flow speed. Pieces ranged from smaller than the width of a hair to over a millimetre across, and many were in a size range that could lodge in small vessels.

The property that best predicted fragment size was the balance between how elastic and how fluid the gel is. Gels that behaved in a more elastic, springy way tended to shatter into smaller, rounder pieces. Gels that behaved more fluidly tended to stretch into longer strands and larger pieces. Firmness on its own and hyaluronic acid concentration were weaker predictors, and flow speed made little difference to fragment size.

At the lowest flow speed, three of the four products blocked one of the first branches of the model, while flow continued through other branches. At higher speeds, none caused a lasting blockage of the main channels.

The authors conclude that injury is likely driven largely by fragments spreading into small downstream vessels, not only by a single plug. They suggest this supports treating the whole affected area with hyaluronidase, the dissolving enzyme, and using ultrasound where a larger blockage is suspected.

How strong is this evidence?

This is laboratory evidence. A plastic model cannot reproduce real blood, clotting, living vessel walls or the body's response to injury. Only four products, one injection amount and one injection speed were tested, and only one artery was modelled. The study also did not include the very smallest vessels, so it could not directly show downstream blockage.

Both authors have ties to companies that make the products tested; one is employed by one of them. That does not invalidate the findings, but it is a reason to look for independent confirmation. Lab models like this are best seen as a way to generate and refine ideas, not as proof of what happens in a patient.

What it means for you

This study does not show that any filler is safe or unsafe, and it should not be used to choose a product. What it does show is that filler properties matter, and that the same complication can behave differently depending on the gel. This is one reason clinicians match products to areas and depths, and why product choice is a medical decision. Our article on filler cross-linking and firmness explains these properties in plain terms.

It also helps explain why blood-flow complications can affect a patch of skin rather than a single spot, and why treatment often involves dissolving filler across the whole affected area. Physician-led clinics keep emergency protocols and hyaluronidase ready for this reason. Our article on vascular occlusion safety describes warning signs to report right away, such as increasing pain, pale or blotchy skin, or any change in vision.

Filler is not suitable for everyone. Pregnancy, breastfeeding, active infection near the area and some immune conditions are common reasons to wait. Usual side effects include swelling, bruising and tenderness, with rare but serious risks such as blocked blood flow.

Where this research could lead

Studies like this help researchers ask better questions. Future models could add the smallest vessels, test different injection amounts and speeds, and use fluids that behave more like blood. Combined with clinical studies, that could eventually help refine how complications are treated, for example how much enzyme is needed and where it should be placed. For now, it adds one more piece to a picture that is still being filled in.

Frequently asked questions

Does a firmer filler mean higher risk?

Not in a simple way. This study found that the balance between elastic and fluid behaviour mattered more than firmness alone, and it did not measure real-world risk at all.

Should I ask for a specific product?

It is fine to ask which product is planned and why. The choice depends on the area, depth and goal, and is best made together with your clinician.

Can lab models predict what will happen to me?

No. They help researchers understand mechanisms, but human anatomy and biology add many factors a model cannot capture.

If you have questions about how filler products differ or how complications are managed, a consultation is a good place to discuss them before any treatment.

Source

Soares DJ, McCarthy AD. The impact of gel parameters on the dispersal and fragmentation of hyaluronic acid gel fillers within an artificial model of arterial embolism. Gels, 2024. Read the study